Resistance > 항암유효성평가지원센터

SERVICE
Overview
Service
Service Workflow

Resistance

We have resistant cell lines to chemotherapeutic drugs with a clarified resistance mechanism to facilitate drug development that can overcome chemotherapeutic drug resistance. When the genetic information of cells is identical, more efficient study of the drug action mechanism and cross-tolerance can be conducted.

List of Models

※In vivo possible cell line

CANCER TYPE

CELL LINE

DRUG

Colon

COLO205

Selumetinib

Leukemia

MOLM-13

Azacitidine, Cytarabine,Decitabine,Quizartinib

THP-1

Decitabine

Lung

A549

AUY922, Cisplatin, Gefitinib,Gemcitabine, Irradiation, Paclitaxel

H209

Cisplatin, Etoposide

H460

Cisplatin, Gemcitabine, Irradiation, Paclitaxel

H1944

AUY922

H1975

AZD9291, WZ4002

H2228

Ceritinib/Lorlatinib, Crizotinib, TAE684, 17-DMAG

H3122

Ceritinib/Lorlatinib, Crizotinib, 17-DMAG

HCC827

Cisplatin, Erlotinib, Gefitinib, Paclitaxel, WZ4002

PC-9

AZD9291, Cisplatin, Erlotinib, Erlotinib/WZ4002, Gefitinib, Gefitinib/ WZ4002, Paclitaxel, WZ4002

기타

Ba/F3/AXL

Ba/F3/del19 EGFR

Ba/F3/del19+T790M+C797S

Ba/F3/L858R

Ba/F3/L858R+T790M+C797S

Ba/F3/CCDC6-RET

Ba/F3/del19+T790M

Ba/F3/EML4-ALK

Ba/F3/L858R+T790M

Ba/F3/FLT3-ITD

Service

  • Studies for novel anti-cancer drug in resistance cell line panels
    • Evaluation of overcoming resistance
    • Compare screening with open-labeled global new drugs
    • Cell viability / Death assay / IC50 calculation
    • In vivo TGI effects, Ex vivo screening
  • Evaluation of resistance-specific biomarkers
    • Pre-validated resistance candidate gene library
    • MOA & POC validation
  • Effective combination strategy
    • Cell viability between a novel drug and resistance candidate gene target drug
    • Synergy index
    • Validation of synergistic target gene

Service example

Evaluation of in vivo resistance inhibition
using an orthotopic xenograft model

Validation of drug efficacy by molecular analysis